Hormonal
GLP-1 receptor agonists (GLP-1RAs) provide modest antidepressant effects and reduce binge eating behaviors, but their impact on suicidality remains uncertain and potentially elevated in high-risk subgroups.
GLP-1 medications like semaglutide and liraglutide may help with mild depression and binge eating, especially if you have diabetes or obesity. However, if you have a history of severe mental health issues or take other psychiatric meds, monitor your mood closely as there may be a small increased risk of suicidal thoughts. The mental health benefits appear to come from direct brain effects, not just weight loss.
Findings suggest modest antidepressant effects, inconsistent associations with suicidality and potential therapeutic benefit in disorders of reward regulation.
Why this rating
Based on a systematic review of 38 studies including RCTs and observational cohorts, but with noted heterogeneity and mixed results.
Source
Psychiatric effects of <scp>GLP</scp> ‐1 receptor agonists: A systematic review of emerging evidence
Brianna Sa et al. · Diabetes Obesity and Metabolism · 2025
DOI 10.1111/dom.70198
More from this paper
- GLP-1 receptor agonists significantly reduce binge eating behaviors and alcohol consumption, offering therapeutic potential for substance use disorders and eating disorders independent of weight loss.Good
- GLP-1 receptor agonists do not exacerbate psychotic symptoms in schizophrenia and provide metabolic benefits, but have not demonstrated consistent effects on core psychiatric symptomatology.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →